newsfilter
← Latest News
GlobeNewswire·

Spyre Therapeutics Announces Grants of Inducement Awards

  • Spyre Therapeutics' independent Compensation Committee approved equity inducement awards on August 3, 2026, for four non-executive employees.
  • The awards include stock options to purchase 19,436 shares of common stock & 6,186 restricted stock units (RSUs).
  • The grants were material to employee acceptance under Nasdaq Listing Rule 5635(c)(4).
  • Stock options have a 10-year term with an exercise price of $94.93 per share.
  • Stock option vesting occurs 1/4 on the first anniversary of the start date, then 1/48 monthly thereafter, subject to continuous service.
  • RSU vesting occurs 1/4 on each anniversary of the start date falling on February 15, May 15, August 15, or November 15, subject to continuous service.
  • All awards are subject to the terms of the 2018 Equity Inducement Plan.
  • Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies targeting α4β7, TL1A, & IL-23.